Kiromic BioPharma, Inc. (KRBP)
| Market Cap | 32.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.81M |
| Shares Out | 7.35M |
| EPS (ttm) | -2.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 117,345 |
| Open | 2.03 |
| Previous Close | 2.01 |
| Day's Range | 1.86 - 2.09 |
| 52-Week Range | 1.81 - 18.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 12, 2021 |
About KRBP
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Lon...
Financial Performance
Financial StatementsNews
Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allo...
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital
Kiromic BioPharma Announces Chief Financial Officer Transition
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Announces Chief Financial Officer Transition
Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma, Inc. - KRBP
NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised to...
Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to A...
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic announces the acquisition of InSilico Solutions leveraging on Bioinformatics and Artificial Intelligence to advance clinical development
Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors
Kiromic BioPharma, Inc. Announces Closing of Public Offering
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma, Inc. Announces Closing of Public Offering
Kiromic BioPharma Stock Plunges After $40M Equity Raise Issued At 24% Discount
Kiromic BioPharma Inc (NASDAQ: KRBP) has priced an underwritten public offering of 8 million shares at $5.00 per share, for gross proceeds of $40 million. The offer price is at a 24% discount on the las...
Kiromic BioPharma, Inc. Announces Pricing of Public Offering
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma, Inc. Announces Pricing of Public Offering
KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf All...
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid Tumors
KRBP Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Th...
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--KRBP Presenting at July 2021 Gamma Delta T Cell summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Therapy
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Vete...
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as COMO
Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Th...
HOUSTON--(BUSINESS WIRE)---- $KRBP #IND--Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy
Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utili...
HOUSTON--(BUSINESS WIRE)---- $KRBP #AI--Kiromic announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Proprietary AI Engine
Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Sh...
HOUSTON--(BUSINESS WIRE)---- $KRBP #INDSubmission--Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter
Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress
Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intel...
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine
Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress
Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Mu...
HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therape...
Kiromic Announces License Agreement With Longwood University for chPD1
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamon...
Kiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamon...
Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target
HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic...
Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with...
Kiromic BioPharma Reports Third Quarter 2020 Financial Results and Continued Corporate Progress
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve...